| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
α-Glucosidase-IN-22 targets α-glucosidase, an enzyme that breaks down carbohydrates into glucose in the intestine. It inhibits α-glucosidase with an IC50 of 0.64 μM. By inhibiting this enzyme, the compound delays carbohydrate digestion and glucose absorption, thereby reducing postprandial blood glucose levels.
|
|---|---|
| ln Vitro |
In vitro, α-Glucosidase-IN-22 (compound 7i) is a potent α-glucosidase inhibitor with an IC50 of 0.64 μM. It demonstrates significant enzyme inhibition in biochemical assays, supporting its potential as an anti-diabetic agent.
|
| ln Vivo |
Specific in vivo activity data for α-Glucosidase-IN-22 are not extensively reported. As an α-glucosidase inhibitor, it would be expected to reduce postprandial blood glucose levels in vivo. Further studies would be required to evaluate its efficacy in animal models of diabetes.
|
| Enzyme Assay |
α-Glucosidase activity is measured using spectrophotometric assays with a chromogenic substrate such as p-nitrophenyl-α-D-glucopyranoside. The enzyme is incubated with the substrate in the presence of α-Glucosidase-IN-22 at varying concentrations, and IC50 values are calculated.
|
| Cell Assay |
Cellular activity of α-Glucosidase-IN-22 is evaluated in cellular models of glucose metabolism. Cells are treated with the compound, and glucose uptake or glycogen synthesis is measured to assess anti-diabetic activity.
|
| Animal Protocol |
In vivo efficacy of α-Glucosidase-IN-22 would typically be evaluated in diabetic animal models. Animals would be administered the compound orally, and postprandial blood glucose levels would be measured to assess efficacy.
|
| ADME/Pharmacokinetics |
α-Glucosidase-IN-22 has a molecular formula of C14H11N3O2S and a molecular weight of 285.32. Its chemical name is 5-((2,4-dihydroxybenzylidene)amino)-1,3-dihydro-2H-benzo[d]imidazole-2-thione. It is soluble in DMSO and stored as a powder at -20°C.
|
| Toxicity/Toxicokinetics |
Toxicological data for α-Glucosidase-IN-22 are limited. The compound is intended for research use only. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
α-Glucosidase-IN-22 (compound 7i) is a benzimidazole and a potent α-glucosidase inhibitor (IC50 = 0.64 μM). It has potential for type 2 diabetes mellitus (T2DM) research. The compound is a valuable tool for studying carbohydrate metabolism and potential therapeutic interventions for diabetes.
|
| Molecular Formula |
C14H11N3O2S
|
|---|---|
| Molecular Weight |
285.321041345596
|
| Exact Mass |
285.06
|
| Elemental Analysis |
C, 58.94; H, 3.89; N, 14.73; O, 11.21; S, 11.24
|
| CAS # |
2870693-28-8
|
| PubChem CID |
157345629
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
1.8
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
20
|
| Complexity |
404
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N(/C1=CC=C2NC(=S)NC2=C1)=C\C1C=CC(O)=CC=1O
|
| InChi Key |
BGXWDJFZASQDKH-VIZOYTHASA-N
|
| InChi Code |
InChI=1S/C14H11N3O2S/c18-10-3-1-8(13(19)6-10)7-15-9-2-4-11-12(5-9)17-14(20)16-11/h1-7,18-19H,(H2,16,17,20)/b15-7+
|
| Chemical Name |
(E)-5-((2,4-dihydroxybenzylidene)amino)-1,3-dihydro-2H-benzo[d]imidazole-2-thione
|
| Synonyms |
compound 7i; α-Glucosidase-IN-22; α-Glucosidase-IN 22; α-Glucosidase IN-22
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~438.10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5048 mL | 17.5242 mL | 35.0484 mL | |
| 5 mM | 0.7010 mL | 3.5048 mL | 7.0097 mL | |
| 10 mM | 0.3505 mL | 1.7524 mL | 3.5048 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
